Last reviewed · How we verify
NCT05974657
Effectiveness and Safety of Lactobacillus Acidophilus LA85 in Preventing Antibiotic-Associated Diarrhea
NA trial testing Probiotic Lactobacillus acidophilus LA85 in Antibiotic Side Effect in 82 participants. Completed in 13 September 2022.
3 August 2022
Quick facts
| Lead sponsor | Wecare Probiotics Co., Ltd. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | health services research |
| Enrollment | 82 |
| Start date | 31 August 2021 |
| Primary completion | 3 August 2022 |
| Estimated completion | 13 September 2022 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Probiotic Lactobacillus acidophilus LA85
Conditions studied
- Antibiotic Side Effect — all drugs for Antibiotic Side Effect →
- Probiotics — all drugs for Probiotics →
- Diarrhea — all drugs for Diarrhea →
Sponsor
Wecare Probiotics Co., Ltd. — full company profile →
Who can join
Adults 18 to 65, any sex, with Antibiotic Side Effect or Probiotics. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized, placebo-controlled, double-blind clinical trial aims to evaluate the efficacy and safety of probiotics as food supplements in preventing antibiotic-associated diarrhea. The study will involve 82 patients who will be randomly assigned to one of two groups: an experimental group receiving a probiotic containing Lactobacillus acidophilus LA85, and a placebo group. The primary outcomes measured include the number of days until the onset of diarrhea, the duration of diarrhea (if it occurs), gastrointestinal quality of life evaluation using the GIQLI questionnaire, and overall patient satisfaction.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Efficacy and Safety of <i>Lactobacillus acidophilus</i> LA85 in Preventing Antibiotic-Associated Diarrhea: A Randomized, Placebo-Controlled Study.
Zhu J, Sun Y, Dong Y, Zhao Y, et al · · 2025 · cited 1× · PMID 40548185 · DOI 10.1002/fsn3.70490
Verify or expand the search:
- PubMed search for NCT05974657
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Antibiotic Side Effect
Currently open trials in the same condition.
- NCT06018792 — Molecular Culture for the Diagnosis of Pediatric Sepsis · recruiting
Other Wecare Probiotics Co., Ltd. trials
Trials by the same sponsor.
- NCT07529457 — Akk09 in Adults With Constipation · NA · not yet recruiting
- NCT07507955 — Probiotics for Constipation Relief in Adults · NA · not yet recruiting
- NCT07462494 — Probiotic Intervention in Constipation · NA · not yet recruiting
- NCT07462481 — Probiotic Improve Constipation · NA · recruiting
- NCT07507929 — Probiotic for Weight Management in Overweight and Obese Adults · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05974657 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wecare Probiotics Co., Ltd.
- Last refreshed: 3 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05974657.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing